Bio-Reference Laboratories Earnings Preview

Watch Bio-Reference Laboratories' (Nasdaq: BRLI  ) earnings report to see if it can beat analyst expectations for the third consecutive quarter. The company will unveil its latest earnings on Thursday, Feb. 23. Bio-Reference Labs is engaged in providing clinical laboratory testing services, mainly to customers in the greater New York metropolitan area as well as to customers in a number of other states.

What analysts say:

  • Buy, sell, or hold?: Half of analysts think investors should stand pat on Bio-Reference Laboratories while the remaining half rate the stock as a buy. Analysts don't like Bio-Reference Laboratories as much as competitor MEDTOX Scientific overall. Two out of two analysts rate MEDTOX Scientific a buy compared to two out of four for Bio-Reference Laboratories. Bio-Reference Laboratories' rating hasn't changed over the past three months.
  • Revenue forecasts: On average, analysts predict $143.1 million in revenue this quarter. That would represent a rise of 17.6% from the year-ago quarter.
  • Wall Street earnings expectations: The average analyst estimate is earnings of $0.21 per share. Estimates range from $0.20 to $0.21.

What our community says:
CAPS All-Stars are solidly backing the stock, with 99% granting it an outperform rating. The greater community backs the All-Stars, as 94.8% give it a rating of outperform. Fools feel positively about Bio-Reference Laboratories, though the message boards have been quiet lately, with only one post in the past 30 days. Even with a robust four out of five stars, Bio-Reference Laboratories' CAPS rating falls a little short of the community's upbeat outlook.

Management:
Bio-Reference Laboratories' profit has risen year over year by an average of 45.6% over the past five quarters.

Now let's get some insight into how efficient management is at running the business. Margins are a representation of how efficiently a company captures portions of sales dollars. Bio-Reference Laboratories' net margins, which reflect what percentage of revenue becomes profit, have been rising year over year for the last four quarters. Here are Bio-Reference Laboratories' reported margins for the last four quarters:

Quarter

Q4

Q3

Q2

Q1

Gross Margin

49.5%

49.6%

47.7%

46.7%

Operating Margin

12.8%

12.4%

9.7%

7.2%

Net Margin

6.9%

6.8%

5.7%

6.6%

For all our Bio-Reference Laboratories-specific analysis, including earnings and beyond, add Bio-Reference Laboratories to My Watchlist.

The Motley Fool owns shares of Bio-Reference Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Earnings estimates provided by Zacks.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1783986, ~/Articles/ArticleHandler.aspx, 8/22/2014 6:52:02 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement